[Frontiers in Bioscience 16, 2427-2450, June 1, 2011]

An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis

Evelien Heylen1, Johan Willemse1, Dirk Hendriks1

1Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium

TABLE OF CONTENTS

1. Abstracts
2. Introduction
3. Biochemical characterization of proCPU
3.1. General considerations
3.2. Genetic features
3.3. Intrinsic enzymatic activity
4. Characteristics of CPU
4.1. Generation of CPU
4.2. Instability of CPU
4.3. CPU at the interface between coagulation and fibrinolysis
5. Measurement of proCPU in plasma
6. Measurement of CPU in circulation
7. ProCPU/CPU system in thrombosis
8. CPU: a new drug target ?
9. Conclusions
10. Acknowledgements
11. References

1. ABSTRACT

Since its discovery more than 20 years ago, a lot has been revealed about the biochemistry and physiological behaviour of carboxypeptidase U (CPU). Recent advances in CPU research include the unravelling of the crystal structure of proCPU and revealing the molecular mechanisms for the marked instability of the active enzyme, CPU. The recent development of two highly sensitive assays has cleared the path toward the direct measurement of CPU in circulation or the determination of CPU generation, rather than the measurement of total proCPU concentration in plasma. Finally, since CPU is known to have a prominent bridging function between coagulation and fibrinolysis, the development of CPU inhibitors as profibrinolytic agents is an attractive new concept and has gained a lot of interest from several research groups and from the pharmaceutical industry. These recent advances in CPU research are reviewed in this literature update.